Back to News
Dec 15, 2025 12:30 PM

Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal

Gilead Sciences Inc. (NASDAQ:GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial.

The trial evaluated the treatment responses of adults with HIV who are virologically suppressed, switching from Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F/TAF) to a fixed-dose combination of bictegravir/lenacapavir (BIC/LEN).

BIC/LEN efficacy was found to be statistically non-inferior to Biktarvy.

Gilead plans to file the Phase 3 results from the ARTISTRY trials with regulatory authorities and submit the detailed findings for presentation at a future scientific congress.

Also Read: Merck’s Investigational Two-Drug Regime Matches ...